Drug Type Small molecule drug |
Synonyms Dubermatinib (USAN/INN), Dubermatinib Tartrate, TP-0903 |
Target |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H30ClN7O2S |
InChIKeyYUAALFPUEOYPNX-UHFFFAOYSA-N |
CAS Registry1341200-45-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 2 | - | - | |
Acute Myeloid Leukemia with FLT3/ITD Mutation | Phase 1 | US | 05 Nov 2020 | |
Relapsing acute myeloid leukemia | Phase 1 | US | 05 Nov 2020 | |
Treatment related acute myeloid leukaemia | Phase 1 | US | 05 Nov 2020 | |
Solid tumor | Phase 1 | JP | 22 Jan 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 14 Dec 2016 | |
BRAF V600 mutation-positive Melanoma | Phase 1 | US | 14 Dec 2016 | |
Colorectal Cancer | Phase 1 | US | 14 Dec 2016 | |
EGFR positive non-small cell lung cancer | Phase 1 | US | 14 Dec 2016 | |
Melanoma | Phase 1 | US | 14 Dec 2016 |
Phase 1/2 | 27 | xrsrpsnezj(habdajqqdb) = cqdioaibjk mdiegjlbmg (iycmuzdxex, 11.8–61.6) View more | - | 08 Jun 2023 | |||
xrsrpsnezj(habdajqqdb) = lvabhfxrmr mdiegjlbmg (iycmuzdxex, 21.1–78.9) View more | |||||||
NCT03013998 (ASCO2022) Manual | Phase 1/2 | 16 | fmtncskbhm(hftzrxbttl) = fbcwcecxra rbyxkkmnrz (nlsywgjhuy, 15.2 - 64.6) View more | Positive | 02 Jun 2022 | ||
Phase 1/2 | 3 | (TP-0903 Monotherapy (25mg Dose of TP-0903)) | uvfbxcubsq(fpmytwigyb) = ehaywojwfn jtsrcaemvg (vxrqfjekyq, wqepqdbnhs - zlehmrwuob) View more | - | 02 Feb 2021 | ||
uvfbxcubsq(fpmytwigyb) = zczajjsjlj jtsrcaemvg (vxrqfjekyq, kfacnvavyg - fytrrqlbov) View more |